Rapport Therapeutics stock gets a buy rating from Jefferies, driven by RAP-219 prospects By Investing.com
On Tuesday, Jefferies initiated coverage on Rapport Therapeutics (NASDAQ:RAPP) stock with a buy rating and a $35.00 price target. The company’s idea is based on the potential of Rapport’s lead drug, RAP-219, to transform the treatment of several central nervous system (CNS) disorders, including epilepsy, which is a market worth more than $1 billion.
An analyst at Jefferies highlighted the unique position of RAP-219 as a highly selective AMPA receptor modulator. Early Phase I data suggest that the drug may offer a unique combination of efficacy and safety. According to the analyst, this may set RAP-219 apart from existing treatments.
Looking ahead, Jefferies expects that the upcoming Phase II data, expected in mid-2025, can show strong and clear results in real epilepsy patients. Such results are predicted to significantly increase Rapport Therapeutics’ stock price by 25-35% or more. This expected data release is seen as a critical event that could potentially jeopardize the RAP platform.
The company’s positive stance on Rapport Therapeutics is based on the belief that the company’s RAP-219 has the potential to disrupt the current treatment paradigm for CNS disorders. The price target of $35.00 reflects this optimistic view of the drug’s prospects in the market.
InvestingPro Insights
As Rapport Therapeutics (NASDAQ:RAPP) grabs Jefferies’ attention with a bullish outlook, real-time data from InvestingPro sheds light on the company’s financial health and market performance. With a market cap of $930.51 million, Rapport Therapeutics has more cash than debt, suggesting a strong balance sheet. This is an important consideration for investors, especially when evaluating the company’s ability to fund ongoing research and development of drugs such as RAP-219.
InvestingPro data also reveals that the stock has had significant returns over the past week, month, and three months, rising 12.07%, 22.31%, and 22.31%, respectively. This momentum is reflected in the stock trading near its 52-week high, with the price at 93.84% of this peak. However, it is important to note that InvestingPro’s current Fair Value estimate stands at $14.28, suggesting a potential valuation at the recent closing price of $25.44.
Investors considering Rapport Therapeutics should also note that despite recent strong performance, the company has been unprofitable over the past twelve months, and pays no dividends to shareholders. For those looking to delve deeper into Rapport’s financial research and market dynamics, there are additional InvestingPro tips available, including insights into the company’s financial metrics and profitability. Using a coupon code PRONEWS24investors can get up to 10% off annual Pro and annual or bi-annual Pro+ subscriptions to access these valuable tips.
This article was created with the support of AI and reviewed by an editor. For more information see our T&C.
